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The first mechanical heart was placed by Liotta and 
Cooley in 1969 in a dying patient at the Texas Heart 
Institute in Houston as a 2 ½-day bridge for a transplant, 
albeit the patient died 32 hours after transplantation.1 
Years later (1982) a totally implantable artificial heart 
(model Jarvik-7) was permanently implanted in a patient 
by DeVries et al at the University of Utah Medical Center 
in Salt Lake City, Utah, USA and the patient lived for 112 
days.2 Subsequent attempts of implantation of a total 
artificial heart (e.g. CardioWest/SynCardia models) have 
limited its use as a bridge to transplantation, like the left- 
or bi-ventricular assist devices (VADs).3-7 The SynCardia 
model (SynCardia Systems Inc., Tuscon, AZ) has been 
approved for compassionate use by the Food and Drug 
Administration (FDA) for patients with end-stage 
biventricular heart failure as a bridge to transplantation 
since 1985 and has had FDA approval since 2004.3-5 The 
SynCardia™ total artificial heart, weighing 180 g, 
providing a stroke volume of 70 cc, is a pneumatically 
driven, pulsatile system capable of flows of >9L/min. It is 
indicated for temporary use as a bridge to transplantation 
in patients with end-stage non-reversible bi-ventricular 
failure. Currently, the recipients of this device are hospital-
bound and attached to a large pneumatic driver. The bridge 
to transplantation rate has been ~80% in >1100 implants. 
In 2010, the FDA gave conditional approval for an 
Investigational Device Exemption clinical study of the 
portable Freedom driver (SynCardia) (www.syncardia.com).  
Researchers and investigators are still exploring ways 
to develop a safe, effective mechanical replacement for the 
human heart. To date, total artificial hearts are still plagued 
with major problems, including thromboembolism, 
bleeding, infection and need for portable drivers.8-11 In 
contrast, ventricular assist devices (VADs)—partial 
artificial hearts—have had a much more successful course 
and are currently in widespread use, despite similar 
drawbacks and limitations (Table 1).6,7,12-14 Thoratec's 
HeartMate II was the first continuous-flow left-VAD 
approved by the FDA for transplant-ineligible heart-failure 
patients (January 20, 2010) as a destination therapy. The 
FDA originally approved HeartMate II as a "bridge to 
transplant" in 2008; the device has been available in 
Europe for both indications since November 2005. Other 
miniaturized VADs approved as bridge to transplant 
include the HeartWare® (CE mark since 2009 and FDA 
approval since 20/11/2012), and CircuLite’s SYNERGY® 
Micro-pump systems (CE mark since 5/9/2012).  
Biventricular support can be achieved using 
paracorporeal biventricular assist devices (BiVADs), the 
total artificial heart (TAH), and implantable VADs.3-5,8,14,15 
However, one needs to understand the difference among 
these various devices. The total artificial heart offers 
biventricular “replacement”, rather than “assistance”, as 
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the device is implanted orthotopically after excision and 
removal of the entire ventricular myocardium and all four 
native valves.3-5,8 In contrast to patients with Bi-VADs, 
patients with the total artificial hearts have no requirements 
for postoperative inotropic support, are not afflicted by 
arrhythmias and have no inflow/ outflow cannulae-related 
complications. The recent development of a portable drive 
may facilitate hospital discharge. Thus, the total artificial 
heart is an effective therapeutic option for the treatment of 
patients dying of heart failure who are not suitable 
candidates for left VADs and are in need of biventricular 
support. Patients who may have a chance for recovery 
should not be considered candidates for the artificial heart. 
Currently, the main difficulty in applying this device as a 
destination therapy is its lack of portability, limited 
durability and questionable safety.  
Device implantation is not risk-free. Perioperative and 
postoperative bleeding, thromboembolic events and 
infections are still plaguing all devices.9,10 The continuous 
flow pumps, heralded as a major breakthrough, may 
increase the risk of gastrointestinal bleeding and have been 
shown to affect von Willebrand's factor.11 Further 
limitations of the LVADs of the continuous flow pump 
type include the acute risk of right heart failure and the 
long-term morbidity of right heart dysfunction in a 
significant number of patients who receive LVADs. Thus, 
there has emerged a renewed interest in developing a 
continuous- (non-pulsatile) or axial-flow (which restores 
some pulsatility) biventricular support system and in the 
use of a total artificial pulsatile heart in order to address the 
morbidity associated with right heart failure.8,14,15  
The growing availability and hopefully a diminishing 
cost13 of mechanical circulatory support devices will allow 
for more widespread use than that offered by heart 
transplants with the limited supply of donor hearts and will 
allow for the implementation of clinical trials and 
technology improvements at a scale that cannot be attained 
by heart transplantation. Thus, we may see a proliferation 
of complex, more miniaturized implantable devices and 
more durable and sustainable with each generation.  
However, despite advances in device technology, the 
dream will remain alive for a totally implantable, self-
contained and energy-sufficient device, which currently 
still remains a major challenge. Recently (December 18, 
2013), a glimpse of real hope was offered by French Dr 
Alain Carpentier whose team implanted a new fully 
implantable artificial heart manufactured by Carmat, in a 
75-year old patient at the Georges Pompidou European 
Hospital in Paris (http://www.carmatsa.com/). The device 
comprises two chambers, each divided by a membrane that 
holds hydraulic fluid on one side 
(http://en.wikipedia.org/wiki/Artificial_heart). A motorized 
pump moves hydraulic fluid in and out of the chambers, 
and that fluid causes the membrane to move; blood flows 
through the other side of each membrane. The blood-
facing side of the membrane is made of tissue obtained 
from a sac that surrounds a cow's heart, to make the device 
more biocompatible. The Carmat device also uses valves 
made from cow heart tissue and has sensors to detect 
increased pressure within the device. That information is 
sent to an internal control system that can adjust the flow 
rate in response to increased demand, such as when a 
patient is exercising. This distinguishes it from previous 
designs that maintain a constant flow rate. The device 
weighs 900 grams; it requires the patient to carry around 
an additional Li-Ion battery. The device will be used as 
destination therapy; its projected lifetime is estimated 
around 5 years (230 million beats).  
 
CONCLUSION 
 A fully implantable autonomous artificial heart without 
any external components remains a major challenge. Apart 
from other major technical demands, it is dependent on the 
capacity of the implanted battery, which should be charged 
transcutaneously.16,17 However, this technology is still in 
the beginning; MIT scientists have founded a company, 
WiTricity (Watertown, MA), which has partnered with 
Thoratec Corp. (Pleasanton, CA) to develop a fully 
implanted left-VAD (www.mddionline.com/article/wireless-
power-medical-devices). For now, the availability of the 
Freedom® portable driver that powers the SynCardia 
temporary Total Artificial Heart will allow stable patients 
to live life at home, while smaller devices are going to be 
available (e.g. the 50cc version in addition to the 70cc 
SynCardia temporary Total Artificial Heart) to fit women 
and younger and smaller stature patients. Finally, the first-
in-man implantation of Carmat’s bioprosthetic artificial 
heart is most encouraging (http://www.carmatsa.com/).  
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Table 1. Currently Used Ventricular Assist Devices (VADs) & Totally Implantable Artificial Heart Devices 
 
Device (Company) Configuration/ 
Function 
Flow Type Weight CO Use Placement/ Flow 
Direction 
Longevity 
Berlin Heart Excor® 
VAD (Berlin Heart) 
LVAD/RVAD/ 
BiVAD 
Pulsatile ? SV 10-
60 ml * 
BTT Extracorporeal ~3y 
Berlin Heart Incor® 
VAD (Berlin Heart) 
LVAD Continuous 
flow 
200 g →6 
L/min 
BTT / 
DT 
Intracorporeal →6y 
Jarvik 2000 (Jarvik 
Heart) 
LVAD Continuous 
flow 
85 g 6 L/min BTT Intracorporeal / LV → 
Desc or Asc Ao 
→8y 
HeartMate II 
(Thoratec)  
LVAD Continuous 
flow 
375 g →10 
L/min 
BTT/ 
DT 
Intracorporeal/ LVA 
→AscAo 
2-8y 
DuraHeart  
(Terumo) 
LVAD Continuous 
flow 
540 g 2-9 
L/min 
BTT/ 
DT 
Intracorporeal/ LVA 
→AscAo 
>4y 
HeartAssist 5/ ** 
DeBakey (MicroMed/ 
ReliantHeart) 
LVAD Continuous 
flow 
92 g →10 
L/min 
BTT/ 
DT 
Intracorporeal/ LVA 
→AscAo 
→6y 
HeartWare HVAD 
(HeartWare) 
LVAD Continuous 
flow 
160 g →10 
L/min 
BTT/ 
DT 
Intracorporeal/ LVA 
→AscAo 
→7y 
Synergy (CircuLite) LVAD Continuous 
flow 
< 25 g 2-4 
L/min 
BTT/ 
DT 
Intracorporeal/ LA 
→Subclavian artery 
→2y 
MiFlow (WorldHeart 
/ HeartWare) 
LVAD Continuous 
flow 
< 30 g → 6 
L/min 
BTT/ 
DT 
Intracorporeal / LVA 
→DescAo 
? 
SynCardia TAH-t 
(Syncardia) *** 
TAH Pulsatile 180 g > 9 
L/min 
BTT Intracorporeal/ 
orthotopic 
~4 y 
Carmat (Carmat) TAH Pulsatile 900 g 3-9 
L/min 
BTT / 
DT 
Intracorporeal / 
orthotopic 
~ 5 y 
AbioCor I / II **** 
(AbioMed) 
TAH  Pulsatile 1090g (I) 
/700g (II) 
> 9 
L/min 
BTT Intracorporeal/ 
orthotopic 
1-2y (model 
I)/ ~ 5y (II) 
 
AscAo = ascending aorta; BTT = bridge-to-transplant; CO = cardiac output; DT = destination therapy; HTx = heart transplant; LA = left atrium; LVA = 
left ventricular apex; LVAD/RVAD = left/right VAD; SV = stroke volume; TAH = total artificial heart  
 
* pediatric versions available  ** remote monitoring capabilities  
*** an evolution of the Jarvik 7 model, renamed CardioWest and then SynCardia (since 2010) 
**** battery is charged through the skin with a special magnetic charger. Energy from the external charger reaches the internal battery through an 
energy transfer device called transcutaneous energy transmission, or TET. An implanted TET device is connected to the implanted battery. An external 
TET coil is connected to the external charger. 
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